Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells

The human Vγ9Vδ2 T cells are a unique T cell type, and recent studies of the biology of Vγ9Vδ2 T cells emphasize the potential exploitation of these cells in immunotherapy of cancer. Vγ9Vδ2 T cells exhibit dual functionality in that they are both antigen presenting cells (APC) and cytotoxic towards cancer cells. We show that Vγ9Vδ2 T cells can kill cancer cell lines from various cancer types such as leukemia, melanoma, prostate-, and breast cancer, with a significantly increased killing upon treatment of the cancer cells with Zoledronic acid. In addition, we show that Vγ9Vδ2 T cells take up tumor antigens gp100 and MART-1 (long peptide and recombinant protein, respectively), and process these antigens for presentation of class I restricted peptides in the context of the HLA-A02.01 molecule, to be recognized by peptide specific cytotoxic CD8 T cells. Moreover, we show that specific inhibition of the proteasome by lactacystin impair recognition by peptide specific CD8 T cells, strongly suggesting proteasome involvement in presentation of the relevant class I restricted peptides. The dual functions; killing and antigen presentation combined with the ease of expanding Vγ9Vδ2 T cells in vitro from peripheral blood lymphocytes to billions of cells, makes Vγ9Vδ2 T cells attractive vehicles for adoptive cell therapy (ACT) in cancer therapy. Thus, Vγ9Vδ2 T cells are broadly tumor specific killers, that concurrently could induce or support tumor specific αβ-T cell responses.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Per thor Straten.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Olofsson, G.H., Idorn, M., Schenker, R. et al. Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells. j. immunotherapy cancer 3, P327 (2015). https://doi.org/10.1186/2051-1426-3-S2-P327

Download citation

Keywords

  • Breast Cancer
  • Cancer Cell
  • Melanoma
  • Zoledronic Acid
  • Peripheral Blood Lymphocyte